ALPS Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.04M Buy
36,206
+1,000
+3% +$57.9K 0.01% 331
2025
Q4
$1.45M Buy
35,206
+19,575
+125% +$759K 0.01% 463
2025
Q3
$615K Sell
15,631
-1,735
-10% -$44.3K ﹤0.01% 632
2025
Q2
$324K Sell
17,366
-6,318
-27% -$119K ﹤0.01% 910
2025
Q1
$430K Sell
23,684
-248
-1% -$5.47K ﹤0.01% 612
2024
Q4
$522K Buy
23,932
+1,635
+7% +$42K ﹤0.01% 596
2024
Q3
$610K Sell
22,297
-618
-3% -$17.2K ﹤0.01% 587
2024
Q2
$593K Buy
+22,915
New +$551K ﹤0.01% 554
2022
Q2
Sell
-3,777
Closed -$175K 1049
2022
Q1
$175K Sell
3,777
-474
-11% -$25.9K ﹤0.01% 810
2021
Q4
$301K Sell
4,251
-235
-5% -$23.6K ﹤0.01% 831
2021
Q3
$523K Buy
4,486
+484
+12% +$56.4K 0.01% 491
2021
Q2
$626K Sell
4,002
-1,488
-27% -$273K 0.01% 489
2021
Q1
$1.04M Buy
5,490
+39
+0.7% +$6.56K 0.01% 395
2020
Q4
$684K Buy
5,451
+1,605
+42% +$182K 0.01% 435
2020
Q3
$418K Buy
3,846
+480
+14% +$56.9K 0.01% 484
2020
Q2
$405K Buy
+3,366
New +$474K 0.01% 481
2019
Q4
Sell
-4,833
Closed -$793K 826
2019
Q3
$793K Sell
4,833
-209
-4% -$39.7K 0.01% 346
2019
Q2
$1.19M Buy
+5,042
New +$1.25M 0.01% 291

Other funds holding DNTH

ALPS Advisors's DNTH Position: Q1 2026 in Review

ALPS Advisors increased its Dianthus Therapeutics (DNTH) stake by 2.8% in Q1 2026, buying an estimated $57.9K and bringing the position to 36,206 shares worth $3.04M. The position accounts for 0.01% of the portfolio, ranked #331.

ALPS Advisors first reported a position in DNTH in Q2 2019 and has held it in 18 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • ALPS Advisors held 36,206 shares of Dianthus Therapeutics worth $3.04M as of Q1 2026.
  • ALPS Advisors bought 1,000 Dianthus Therapeutics shares in Q1 2026, an estimated $57.9K.
  • Dianthus Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #331 holding.
  • ALPS Advisors first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 18 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.